The Latest Breaking News from Pfizer

With the Food and Drug Administration’s Aug. 21, 2023, approval of the first vaccine against respiratory syncytial virus, or RSV, for use during late pregnancy, the U.S. will soon have a major new tool at its disposal to protect infants against the highly contagious virus.

There are now RSV vaccines approved for older adults and for pregnant people, and antibody shots (not vaccines) available for babies. What's the difference?

U.S. regulators have approved the first RSV vaccine for pregnant women to protect their newborns

The Food and Drug Administration has approved the first vaccine for expectant mothers to shield their babies from RSV.

Pfizer stock and Moderna stock dipped Friday — giving back some of their late Thursday gains on an upswing related to their updated Covid shots.

Health officials reiterate support for private provision as lower age limit for NHS booster vaccines raised to 65

Some 47 Fortune 500 CEOs have spent time as management consultants but first took more junior roles.

If you thought social media had a hand in getting Trump elected, watch what happens when you throw AI into the mix

Maybe it's not a full-blown summer surge but COVID numbers are ticking up. For those with concerns due to personal risk factors or the start of the school year, the booster question is top of mind.

The healthcare sector has trailed far behind the overall stock market so far this year, creating 'opportunities.'

A new method called ‘skeletal editing’ offers a hugely simplified way to alter matter, paving the way for world-changing innovations in personalised medicine and sustainable plastics